Ovid Therapeutics

In a recent BioCentury Inc. article by Lauren Martz, Dr. Jeremy M. Levin, Ovid CEO, and Meg Alexander, President and COO, share how we’re working on cracking the code on how to drug KCC2. We are pioneering the direct activation of KCC2 to treat a range of neurological disorders with a library of compounds. As Meg points out in the article, “By going after KCC2, which is fundamental to essentially, intrinsically bringing hyperexcited neurons back into balance, all of a sudden, we can start to unlock a number of different indications.” The breadth of our KCC2 library of compounds, including lead asset OV350, is also highlighted, with OV350 poised to move into a phase 1 study in 2025. Check out the full article to learn more. https://lnkd.in/ggWR7wE7

Before we head into #JPM2025 Meg Alexander, President and COO, will be joining a panel at Longwood Healthcare Leaders San Francisco CEO to discuss a topic that we find incredibly important, “the value of company culture.” If you are attending, don’t miss this insightful conversation! Learn more about the event: https://lnkd.in/e6r5Z3je

Labiotech.eu’s Jules ADAM recently published an article looking back at the biotech industry in 2024 and featured Ovid CEO Dr. Jeremy M. Levin’s perspective on the field’s growing focus on neurological disorders. Dr. Levin draws parallels to the GLP-1 revolution in cardiometabolic diseases. With an aging population and rising prevalence of neurodegenerative diseases, he predicts a similar breakthrough for the field of neurology. Read the article below to learn more. https://lnkd.in/dybH4xJk #Biotech #Neurology

Zhong Zhong, Ovid’s Chief Scientific Officer, will be presenting findings on how OV329, a potent GABA-AT inhibitor, does not accumulate in the mouse retina at the 2024 American Epilepsy Society Annual Meeting. If you’re at AES be sure to attend Zhong’s presentation to learn more! Additional details can be found here: https://lnkd.in/eURpJvpH #AES2024

Ovid’s SVP of Clinical Development, Julia Tsai, will be presenting at this year’s American Epilepsy Society Annual Meeting. She will discuss a study that found OV329 rapidly increases brain GABA levels and effectively suppresses seizures in a rat model. Be sure to check out Julia’s presentation if you’ll be at AES! Learn more: https://lnkd.in/eURpJvpH #AES2024

Toshiya Nishi, Ovid’s Senior Director of Drug Discovery, will be presenting on the anticonvulsant efficacy of the KCC2 activator, OV350, in a rat model of nerve agent poisoning at the 2024 American Epilepsy Society Annual Meeting. If you’re attending AES, come speak with Toshiya about the latest preclinical research in KCC2! Learn more: https://lnkd.in/eURpJvpH #AES2024

We’re pleased to share that Ovid will be presenting multiple posters supporting our pipeline programs targeting neuronal hyperexcitability at the 2024 American Epilepsy Society Annual Meeting in Los Angeles. Check out the animation below for information on our poster sessions and learn more here: https://lnkd.in/eURpJvpH. #AES2024

This fall, we were delighted to gather Ovidians and their families for our annual Fall Family Farm Day. It was a memorable day filled with laughter and connection against the backdrop of the autumn season – a  reminder of the importance of community and the many things we have to be thankful for. This #Thanksgiving season we are especially grateful for our incredible team and their dedication to supporting patient communities affected by epilepsies and other neurological conditions. #HappyThanksgiving

November is Epilepsy Awareness Month. 💜 We’re honored to feature a conversation with Beth Dean, MBA, MPA, CEO of CURE Epilepsy. During CURE Epilepsy's SUDEP workshop hosted at our NYC office, we had the chance to speak with Beth about the importance of awareness, advocacy, and advancing research for the epilepsy community. Watch the video to hear her insights. #EpilepsyAwarenessMonth

Did you know that KCC2 is considered one of the most exciting therapeutic targets in neuroscience today? Directly activating KCC2 may open new avenues for potential treatments across a range of neurological conditions, including neuropsychiatric, neurodevelopmental and neurodegenerative diseases as well as pain, epilepsies and other seizure disorders. Learn more about KCC2 below and by viewing our KCC2 Download Day presentation: https://lnkd.in/eCBq8gFC